Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 18Non-Muscle Invasive Bladder Neoplasms 12Carcinoma, Transitional Cell 11Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Anus Neoplasms 5Lung Neoplasms 4Neoplasms 3Carcinoma, Hepatocellular 3Carcinoma 3Urologic Neoplasms 2Urologic Diseases 2Urogenital Neoplasms 2Urinary Bladder Diseases 2Stomach Neoplasms 2Neoplasms by Site 2Colonic Neoplasms 2Anal Canal Carcinoma 2Uterine Cervical Neoplasms 1Urogenital Diseases 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mycobacterium Infections 1

Interventions

Carboplatin 17Cisplatin 14Paclitaxel 12Pemetrexed 11pembrolizumab 9Gemcitabine 7Docetaxel 6Sorafenib 5osimertinib 4durvalumab 4130-nm albumin-bound paclitaxel 4padeliporfin 3cabozantinib 3atezolizumab 3Taxes 3Radiotherapy 3Mitomycin 3Magnetic Resonance Spectroscopy 3Cetuximab 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2Sunitinib 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiation 2Nivolumab 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma × Mitomycin × Clear all
NCT02526953 2021-02-09

Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients

Blokhin's Russian Cancer Research Center

Phase 3 Unknown
314 enrolled
Gastrointestinal

Anus Diseases, Anus Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Neoplasms, Neoplasms, Squamous Cell

NCT02793128 2020-12-22

Olympus

UroGen Pharma Ltd.

Phase 3 Completed
71 enrolled 16 charts 1 FDA
Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT04006691 2020-05-07

Retreatment

UroGen Pharma Ltd.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡